The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections

The ARESC (Antimicrobial Resistance Epidemiological Survey on Cystitis) study is an international survey to investigate the prevalence and susceptibility of pathogens causing cystitis. Female patients (n = 4264) aged 18-65 years with symptoms of uncomplicated cystitis were consecutively enrolled in...

Descripción completa

Detalles Bibliográficos
Autores: Schito, GC, Naber, KG, Botto, H, Palou, J, Mazzei, T, Gualco, L, Marchese, A
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2009
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p13081
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=13081
https://hal.science/hal-00556347
Access Level:acceso abierto
Palabra clave:Escherichia coli
Cystitis
Fosfomycin
Ciprofloxacin
Amoxicillin/clavulanic acid
id ES_7cb09d189c19a4f84e42ce3a93a43b1e
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p13081
network_acronym_str ES
network_name_str España
repository_id_str
spelling The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infectionsSchito, GCNaber, KGBotto, HPalou, JMazzei, TGualco, LMarchese, AEscherichia coliCystitisFosfomycinCiprofloxacinAmoxicillin/clavulanic acidThe ARESC (Antimicrobial Resistance Epidemiological Survey on Cystitis) study is an international survey to investigate the prevalence and susceptibility of pathogens causing cystitis. Female patients (n = 4264) aged 18-65 years with symptoms of uncomplicated cystitis were consecutively enrolled in nine European countries as well as Brazil during 2003-2006. Pathogens were identified and their susceptibility to nine antimicrobials was determined. Escherichia coli accounted for 76.7% of isolates. Among E. coli, 10.3% of the isolates were resistant to at last three different classes of antimicrobial agents. Resistance was most common to ampicillin (48.3%), trimethoprim/sulfamethoxazole (29.4%) and nalidixic acid (18.6%). Fosfomycin, mecillinam and nitrofurantoin were the most active drugs (98.1%, 95.8% and 95.2% susceptible strains, respectively) followed by ciprofloxacin, amoxicillin/clavulanic acid and cefuroxime (91.7%, 82.5% and 82.4%, respectively). Resistance to ciprofloxacin was >10% in Brazil, Spain, Italy and Russia. Overall, Proteus mirabilis were more susceptible to beta-lactams and less susceptible to non-beta-lactams than E. coli, whereas Klebsiella pneumoniae strains, which are intrinsically resistant to ampicillin, were less susceptible to mecillinam (88.8%), fosfomycin (87.9%), cefuroxime (78.6%) and nitrofurantoin (17.7%). Resistance was rare in Staphylococcus saprophyticus, with the exception of ampicillin (36.4%) and trimethoprim/sulfamethoxazole (10.2%). In Italy, Spain, Brazil and Russia, the countries most affected by antimicrobial resistance, extended-spectrum beta-lactamase (ESBL) enzymes (mainly CTX-M type) were detected in 48 strains (39 E. coli, 6 K. pneumoniae and 3 P. mirabilis). Despite wide intercountry variability in bacterial susceptibility rates to the other antimicrobials tested, fosfomycin and mecillinam have preserved their in vitro activity in all countries investigated against the most common uropathogens. (C) 2009 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.ELSEVIER2009info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=13081https://hal.science/hal-00556347INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTSISSN: 09248579ISSNe: 18727913reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p130812026-06-14T12:41:47Z
dc.title.none.fl_str_mv The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections
title The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections
spellingShingle The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections
Schito, GC
Escherichia coli
Cystitis
Fosfomycin
Ciprofloxacin
Amoxicillin/clavulanic acid
title_short The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections
title_full The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections
title_fullStr The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections
title_full_unstemmed The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections
title_sort The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections
dc.creator.none.fl_str_mv Schito, GC
Naber, KG
Botto, H
Palou, J
Mazzei, T
Gualco, L
Marchese, A
author Schito, GC
author_facet Schito, GC
Naber, KG
Botto, H
Palou, J
Mazzei, T
Gualco, L
Marchese, A
author_role author
author2 Naber, KG
Botto, H
Palou, J
Mazzei, T
Gualco, L
Marchese, A
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv Escherichia coli
Cystitis
Fosfomycin
Ciprofloxacin
Amoxicillin/clavulanic acid
topic Escherichia coli
Cystitis
Fosfomycin
Ciprofloxacin
Amoxicillin/clavulanic acid
description The ARESC (Antimicrobial Resistance Epidemiological Survey on Cystitis) study is an international survey to investigate the prevalence and susceptibility of pathogens causing cystitis. Female patients (n = 4264) aged 18-65 years with symptoms of uncomplicated cystitis were consecutively enrolled in nine European countries as well as Brazil during 2003-2006. Pathogens were identified and their susceptibility to nine antimicrobials was determined. Escherichia coli accounted for 76.7% of isolates. Among E. coli, 10.3% of the isolates were resistant to at last three different classes of antimicrobial agents. Resistance was most common to ampicillin (48.3%), trimethoprim/sulfamethoxazole (29.4%) and nalidixic acid (18.6%). Fosfomycin, mecillinam and nitrofurantoin were the most active drugs (98.1%, 95.8% and 95.2% susceptible strains, respectively) followed by ciprofloxacin, amoxicillin/clavulanic acid and cefuroxime (91.7%, 82.5% and 82.4%, respectively). Resistance to ciprofloxacin was >10% in Brazil, Spain, Italy and Russia. Overall, Proteus mirabilis were more susceptible to beta-lactams and less susceptible to non-beta-lactams than E. coli, whereas Klebsiella pneumoniae strains, which are intrinsically resistant to ampicillin, were less susceptible to mecillinam (88.8%), fosfomycin (87.9%), cefuroxime (78.6%) and nitrofurantoin (17.7%). Resistance was rare in Staphylococcus saprophyticus, with the exception of ampicillin (36.4%) and trimethoprim/sulfamethoxazole (10.2%). In Italy, Spain, Brazil and Russia, the countries most affected by antimicrobial resistance, extended-spectrum beta-lactamase (ESBL) enzymes (mainly CTX-M type) were detected in 48 strains (39 E. coli, 6 K. pneumoniae and 3 P. mirabilis). Despite wide intercountry variability in bacterial susceptibility rates to the other antimicrobials tested, fosfomycin and mecillinam have preserved their in vitro activity in all countries investigated against the most common uropathogens. (C) 2009 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
publishDate 2009
dc.date.none.fl_str_mv 2009
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=13081
https://hal.science/hal-00556347
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=13081
https://hal.science/hal-00556347
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv ELSEVIER
publisher.none.fl_str_mv ELSEVIER
dc.source.none.fl_str_mv INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
ISSN: 09248579
ISSNe: 18727913
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869411609406865408
score 15,811543

Similares en LA Referencia